ARTICLE | Deals
Myovant’s deal with Pfizer for $650M up front is the latest sign women’s health is back
December 28, 2020 11:28 PM UTC
Pfizer’s partnership with Myovant sends another signal that plenty of opportunity still exists in women’s health, despite recent pharma exits.
In teaming up with Pfizer Inc. (NYSE:PFE) to develop and commercialize relugolix, Myovant Sciences GmbH (NYSE:MYOV) will receive an upfront payment of $650 million and is eligible for $200 million in regulatory milestones around a combination tablet, and tiered sales milestones for a total deal value of up to $4.2 billion...
BCIQ Target Profiles